TAK-079 is a human IgG1 mAb with a high affinity for CD38 that is being developed for the treatment of MM and autoimmune diseases [124]; it is currently being evaluated in a phase I/IIa clinical trial administered as a single agent in RRMM patients (NCT03439280). The gene discussed is CD38; the disease is Miyoshi myopathy.